Novavax Partners With Ranbaxy

Novavax, a specialty biopharmaceutical company, and Ranbaxy Laboratories, have entered into an agreement to evaluate a new transdermal product (this is a new product and is not related to ESTRASORB). This product has been formulated using Novavax's proprietary micellar nanoparticle (MNP) technology. "This agreement demonstrates the merits of our MNP technology to other companies as a value-added proprietary delivery technology for novel drug candidates. This is an example of the commercial and development opportunities micellar nanoparticle technology offers Novavax and our partners," said Nelson M. Sims, President and CEO, Novavax.

Yahoo News (http://biz.yahoo.com/prnews/050316/to189_1.html)